FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2141045409> ?p ?o ?g. }

• W2141045409 endingPage "146" @default.
• W2141045409 startingPage "137" @default.
• W2141045409 abstract "Background PHOENIX 1 was a phase III, randomized, double-blind, placebo-controlled study that demonstrated the long-term efficacy and safety of ustekinumab in patients with moderate-to-severe psoriasis. Objectives To assess the effect of ustekinumab maintenance therapy on health-related quality of life (HRQoL) in PHOENIX 1 patients. Patients and methods Patients (n = 766) were randomized to receive ustekinumab 45 mg (n = 255) or 90 mg (n = 256) at weeks 0 and 4 and every 12 weeks thereafter, or placebo (n = 255) at weeks 0 and 4 with crossover to ustekinumab at week 12. Ustekinumab-randomized patients achieving at least 75% improvement in Psoriasis Area and Severity Index (PASI) 75 at weeks 28 and 40 were re-randomized at week 40 to continue ustekinumab or be withdrawn until loss of therapeutic effect. HRQoL was assessed using the SF-36 and Dermatology Life Quality Index (DLQI). Results At baseline, more than 97% had a DLQI > 1 and the average DLQI was > 10, indicating a significant impact on patients’ HRQoL. Significantly greater proportions of patients receiving ustekinumab 45 and 90 mg achieved a normalized DLQI score (≤ 1) compared with placebo (53·2%, 52·4% and 6·0%, respectively, both P < 0·001) at week 12 and achieved a clinically meaningful improvement (increase of at least five points) in SF-36 physical (23·1%, 33·7% and 15·6%) and mental (25·5%, 31·3% and 14·8%) component summary scores. At week 12, changes in individual DLQI and SF-36 domains were significantly better in each ustekinumab group vs. placebo (P < 0·001). The magnitude of improvement across SF-36 scales was greatest for the bodily pain and social functioning domains. Improvements in HRQoL were sustained with maintenance ustekinumab therapy through at least 1 year. Regression analysis showed that, after adjustment for improvement in PASI or Physician’s Global Assessment (PGA), ustekinumab-treated patients demonstrated significant improvements in DLQI. Conclusions Ustekinumab improves HRQoL in patients with moderate-to-severe psoriasis. Patient-reported outcomes measured a treatment effect beyond that indicated by clinical measures." @default.
• W2141045409 created "2016-06-24" @default.
• W2141045409 creator A5001440423 @default.
• W2141045409 creator A5008286260 @default.
• W2141045409 creator A5015195905 @default.
• W2141045409 creator A5020632357 @default.
• W2141045409 creator A5038505651 @default.
• W2141045409 creator A5063001450 @default.
• W2141045409 creator A5071777072 @default.
• W2141045409 date "2009-11-09" @default.
• W2141045409 modified "2023-09-26" @default.
• W2141045409 title "Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial" @default.
• W2141045409 cites W1980773105 @default.
• W2141045409 cites W1983185705 @default.
• W2141045409 cites W1994127723 @default.
• W2141045409 cites W2008223306 @default.
• W2141045409 cites W2010271323 @default.
• W2141045409 cites W2012581664 @default.
• W2141045409 cites W2033275545 @default.
• W2141045409 cites W2034992158 @default.
• W2141045409 cites W2038049217 @default.
• W2141045409 cites W2038741370 @default.
• W2141045409 cites W2055018575 @default.
• W2141045409 cites W2060886633 @default.
• W2141045409 cites W2067327580 @default.
• W2141045409 cites W2071343804 @default.
• W2141045409 cites W2080090843 @default.
• W2141045409 cites W2080165152 @default.
• W2141045409 cites W2086861262 @default.
• W2141045409 cites W2088314729 @default.
• W2141045409 cites W2093455167 @default.
• W2141045409 cites W2096445837 @default.
• W2141045409 cites W2096991001 @default.
• W2141045409 cites W2112031699 @default.
• W2141045409 cites W2116956799 @default.
• W2141045409 cites W2122897116 @default.
• W2141045409 cites W2124549038 @default.
• W2141045409 cites W2146050736 @default.
• W2141045409 cites W2154418381 @default.
• W2141045409 cites W2161895264 @default.
• W2141045409 cites W2168505126 @default.
• W2141045409 cites W2170270641 @default.
• W2141045409 cites W4233561050 @default.
• W2141045409 cites W4248269869 @default.
• W2141045409 cites W4249483860 @default.
• W2141045409 cites W4292806894 @default.
• W2141045409 doi "https://doi.org/10.1111/j.1365-2133.2009.09491.x" @default.
• W2141045409 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19903183" @default.
• W2141045409 hasPublicationYear "2009" @default.
• W2141045409 type Work @default.
• W2141045409 sameAs 2141045409 @default.
• W2141045409 citedByCount "84" @default.
• W2141045409 countsByYear W21410454092012 @default.
• W2141045409 countsByYear W21410454092013 @default.
• W2141045409 countsByYear W21410454092014 @default.
• W2141045409 countsByYear W21410454092015 @default.
• W2141045409 countsByYear W21410454092016 @default.
• W2141045409 countsByYear W21410454092017 @default.
• W2141045409 countsByYear W21410454092018 @default.
• W2141045409 countsByYear W21410454092019 @default.
• W2141045409 countsByYear W21410454092020 @default.
• W2141045409 countsByYear W21410454092021 @default.
• W2141045409 countsByYear W21410454092022 @default.
• W2141045409 countsByYear W21410454092023 @default.
• W2141045409 crossrefType "journal-article" @default.
• W2141045409 hasAuthorship W2141045409A5001440423 @default.
• W2141045409 hasAuthorship W2141045409A5008286260 @default.
• W2141045409 hasAuthorship W2141045409A5015195905 @default.
• W2141045409 hasAuthorship W2141045409A5020632357 @default.
• W2141045409 hasAuthorship W2141045409A5038505651 @default.
• W2141045409 hasAuthorship W2141045409A5063001450 @default.
• W2141045409 hasAuthorship W2141045409A5071777072 @default.
• W2141045409 hasConcept C126322002 @default.
• W2141045409 hasConcept C142724271 @default.
• W2141045409 hasConcept C159110408 @default.
• W2141045409 hasConcept C16005928 @default.
• W2141045409 hasConcept C168563851 @default.
• W2141045409 hasConcept C1862650 @default.
• W2141045409 hasConcept C204787440 @default.
• W2141045409 hasConcept C27081682 @default.
• W2141045409 hasConcept C2776173921 @default.
• W2141045409 hasConcept C2777011040 @default.
• W2141045409 hasConcept C2777138892 @default.
• W2141045409 hasConcept C2778975655 @default.
• W2141045409 hasConcept C2779134260 @default.
• W2141045409 hasConcept C2779951463 @default.
• W2141045409 hasConcept C2780564577 @default.
• W2141045409 hasConcept C71924100 @default.
• W2141045409 hasConcept C87813604 @default.
• W2141045409 hasConceptScore W2141045409C126322002 @default.
• W2141045409 hasConceptScore W2141045409C142724271 @default.
• W2141045409 hasConceptScore W2141045409C159110408 @default.
• W2141045409 hasConceptScore W2141045409C16005928 @default.
• W2141045409 hasConceptScore W2141045409C168563851 @default.
• W2141045409 hasConceptScore W2141045409C1862650 @default.
• W2141045409 hasConceptScore W2141045409C204787440 @default.
• W2141045409 hasConceptScore W2141045409C27081682 @default.
• W2141045409 hasConceptScore W2141045409C2776173921 @default.

• next